Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering
MADISON, WIS., June 4, 2013 –Cellular Dynamics International, Inc., a leading developer of stem cell technologies for in vitro use in drug discovery, toxicity testing and chemical safety, stem cell banking, and in vivo and cell-based therapeutic research, today announced that it has filed a registration statement on June 3, 2013, on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The registration statement filed on June 3 represents the Company’s initial public filing pursuant to the provisions of the Jumpstart Our Business Startups (JOBS) Act of 2012. CDI’s common stock is expected to be listed on the NASDAQ Global Market under the symbol “ICEL.” The number of shares to be offered and the price range for the offering have not been determined.
J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. Cowen and Company, LLC and Leerink Swann LLC are acting as co-managers.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204.